# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sonny Liston (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX007-SYN
- Date: 2026-06-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Malcolm Achebe-Whitford, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of high blood pressure, seen the same day by cardiology. **S**

## History of present illness

Sonny Liston returns two weeks after intake and is seen the same day by Dr. Lindqvist-Owusu. He wore the ambulatory blood pressure monitor for 24 hours last week, including a training session, and had an echocardiogram this morning. His intake blood tests were normal apart from a mildly raised AST and GGT, which were explained to him in plain words as signs that alcohol is affecting his liver. He has cut his drinking from about 25 drinks a week to about 18 by keeping a tally of marks on a card, but found the weekends hard. He feels well and has no headaches, chest pain, breathlessness or palpitations. He wants to know whether he can fight again this year. No thoughts of suicide. **S**

| Element | Detail |
|---|---|
| Ambulatory monitoring | Daytime 146/94, nighttime 132/84, 24-hour 142/91 mmHg |
| Echocardiogram | Mild concentric LVH (12 mm); ejection fraction 60 percent; normal diastolic function |
| Drinking | About 18 drinks a week, from about 25 |
| Urine albumin | 18 mg/g, normal |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, fainting or ankle swelling |
| Respiratory | Negative | No breathlessness beyond what he expects in hard sparring |
| Neurological | Negative | No headaches, vision change or weakness |
| Psychiatric | Negative | Mood all right; no thoughts of suicide |

4 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/96 mmHg; pulse 56 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 98.6 kg; BMI 28.8 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 148/96 mmHg (average of two, large cuff); pulse 56; weight 98.6 kg |
| Cardiovascular | Regular slow rhythm; no murmur, gallop or edema; foot pulses normal |
| Respiratory | Clear to auscultation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **High blood pressure reading** (R03.0). Ambulatory monitoring confirms hypertension in the stage 2 range (daytime average 146/94 mmHg), with no white-coat effect. Dr. Lindqvist-Owusu finds mild concentric left ventricular hypertrophy that fits hypertension added to training, with normal function; kidneys, urine albumin, glucose and thyroid are normal, and there is no sign of a secondary cause beyond alcohol. The high reading that brought him in is resolved into the diagnosis of hypertension. **S**
   - Start amlodipine 5 mg and valsartan 160 mg in one tablet each morning.
   - Potassium and creatinine at the four-week visit.
   - A talking home blood pressure monitor with a large display: two readings each morning, photographed and sent to the clinic by text message.
   - Lower-salt eating and fewer drinks.
   - No bouts until his blood pressure is controlled; then the commission physician's check.
2. **Alcohol use disorder, moderate** (F10.20). A good start on his own goal; weekends are the hard part. He wants to keep trying without medicine for now. **S**
   - Keep the tally card; plan alcohol-free weekend evenings with his trainer's sessions.
   - Naltrexone, acamprosate and topiramate explained again for if he wants help.
   - Safety plan reviewed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, large cuff, average of two readings), weight and BMI, heart sounds | Every visit | Completed today | 148/96 mmHg; weight 98.6 kg; no gallop |
| Examination | Out-of-office blood pressure (ambulatory or home monitoring) | At diagnosis and after each treatment change | Completed today | 24-hour ambulatory monitoring last week: daytime 146/94, nighttime 132/84 mmHg; confirms hypertension |
| Laboratory | Potassium, creatinine and eGFR | Baseline; two to four weeks after starting an ARB; then every six months on an ARB | Ordered | Baseline potassium 4.1 mmol/L and creatinine 1.1 mg/dL (eGFR 89) at intake; recheck at four weeks after starting valsartan |
| Laboratory | Lipids, glucose or A1c, urine albumin-to-creatinine ratio, TSH | At diagnosis, then yearly (TSH at diagnosis) | Up to date | At intake: LDL 122, HDL 58 mg/dL; A1c 5.4%; urine albumin-to-creatinine ratio 18 mg/g; TSH 1.6 |
| Imaging | 12-lead ECG | Baseline at diagnosis | Up to date | At intake: sinus bradycardia 56; LVH voltage criteria without repolarization change |
| Imaging | Echocardiogram | At diagnosis for stage 2 hypertension or suspected LVH; repeat as indicated | Completed today | Mild concentric LVH (12 mm); ejection fraction 60 percent; normal diastolic function and aortic root |
| Examination | Fundoscopic examination | Yearly | Due | At the preventive visit |
| Survey | Cardiovascular risk estimate | Yearly | Due | At the preventive visit; the pooled cohort equations apply only from 40 |
| Medication safety | Antihypertensive tolerance (ankle edema, dizziness) and adherence by teach-back | Each follow-up and each dose change | Not indicated | No antihypertensive until today; teach-back of the new tablet done with the picture card |
| Referral | Fitness to compete (AHA/ACC athlete statement) | At diagnosis and before returning to competition | Completed today | Cardiology: no competition until controlled; then clearance with a repeat check |
| Survey | Drinking (AUDIT-C, drinks per week, drinking days) | Every follow-up during treatment; full AUDIT at about four months | Up to date | AUDIT 16 at intake; about 18 drinks a week now by his tally; next AUDIT-C at four weeks |
| Laboratory | Liver tests (AST, ALT, GGT) | Baseline; about two months after starting naltrexone or cutting down; then as indicated | Up to date | At intake: AST 46, ALT 38, GGT 88 U/L; recheck in about two months |
| Survey | Suicide-risk review (structured questions) and safety plan | Every visit | Completed today | No thoughts of suicide; safety plan card reviewed |
| Self-management | Health literacy: teach-back, picture card, read-aloud consent, voice reminders | Every visit | Completed today | Plan explained in two key points; he repeated them back correctly; consent for the echocardiogram read aloud |

## Goal progress

- Confirm or rule out hypertension with out-of-office readings before any medicine. Outcome by 2026-06-23: Ambulatory monitoring confirmed stage 2 hypertension (daytime 146/94 mmHg). **S**
- Blood pressure under 130/80 mmHg in the clinic and at home by four months. In progress; target 2026-10-20. **S**
- Drink within the goal he set: no more than 14 drinks a week and no more than 4 on any day, and none in the two weeks before a fight. In progress; target 2026-10-20. **S**
- Explain his medicines and blood pressure plan back in his own words. In progress; target 2026-07-21. **S**

## Medication changes

- Started: Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morning **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- Hypertension in Adults: Screening (2021), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026), Aether Forge
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (Black HR, et al.) (2015), American Heart Association and American College of Cardiology (Circulation 2015)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024), Agency for Healthcare Research and Quality

## Follow-up

- Four-week review with potassium, creatinine and AUDIT-C. Home readings each morning by photo message. Call 988 or the clinic at any time if thoughts of suicide arise. **S**
- Next scheduled visit 2026-07-21: four-week review: blood pressure on treatment, potassium and creatinine, drinking, and medicine teach-back. **S**
